Evaluation of nivolumab for ototoxic effects: An animal study in rats

Basit Öğe Kaydı
dc.authorid0000-0002-9639-0204
dc.authorid0000-0002-9639-0204
dc.contributor.authorGüler, İsmail
dc.contributor.authorKuzucu, İhsan
dc.contributor.authorBaklacı, Deniz
dc.contributor.authorKum, Oğuzhanrauf
dc.contributor.authorÖzhamam Uçaryılmaz, Esra
dc.contributor.authorÖzcan, Müge
dc.date.accessioned2020-09-09T10:18:54Z
dc.date.available2020-09-09T10:18:54Z
dc.date.issued2020
dc.departmentTıp Fakültesi
dc.descriptionKuzucu, İhsan ( Aksaray, Yazar )
dc.description.abstractOBJECTIVES: The aim of this study was to assess whether nivolumab is ototoxic in rats and whether this ototoxicity is dose-dependent. MATERIALS AND METHODS: Twelve rats were divided into two groups: Group 1 (control group, 6 rats, 12 ears) received intraperitoneal saline for 14 days. Group 2 (study group, 6 rats, 12 ears) and received two doses of 3 mg/kg intraperitoneal nivolumab within 14 days. Auditory brainstem responses (ABRs) were performed preoperatively and 4 and 8 weeks postoperatively. We compared between the groups, morphologic appearance of spiral ganglion cells and organ of Corti and density of spiral ganglion cells (measured with conventional light microscope connected to a personal computer). RESULTS: In our control group, both spiral ganglion and organ of corti had a normal morphological appearance. In our study group, spiral ganglion cells had a normal morphological appearance. However, some sections showed possibly mild degenerative changes in the organ of corti. Of 12 samples in the study group, four had a significant loss of density of spiral ganglion cells compared to the control group. The baseline ABR thresholds did not significantly differ between the groups (p=0.713). There was no statistically significant difference between the groups regarding ABR thresholds at week 4 (p=0.347). However, a statistically significant difference was observed in the ABR thresholds at week 8 (p=0.045). CONCLUSION: The results of our study showed that nivolumab treatment has ototoxic effects. Based on our results, we recommend monitoring the changes in the hearing ability of chemotherapy patients.
dc.identifier.doi10.5152/iao.2020.7123
dc.identifier.endpage221en_US
dc.identifier.issn2148-3817
dc.identifier.issue2en_US
dc.identifier.pmid32510456
dc.identifier.scopusqualityN/A
dc.identifier.startpage218en_US
dc.identifier.urihttps:/dx.doi.org/10.5152/iao.2020.7123
dc.identifier.urihttps://hdl.handle.net/20.500.12451/7671
dc.identifier.volume16en_US
dc.identifier.wosWOS:000562022100013
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofThe journal of international advanced otology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOtotoxicity
dc.subjectNivolumab
dc.subjectImmunotherapy
dc.subjectAnimal Study
dc.titleEvaluation of nivolumab for ototoxic effects: An animal study in rats
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
guler-ismail-2020.pdf
Boyut:
2.59 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu